WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592339

CAS#: 104958-90-9

Description: Sanazole is a 3-nitrotriazole cpd. It affects the human cervical cancer cell line.

Chemical Structure

CAS# 104958-90-9

Theoretical Analysis

MedKoo Cat#: 592339
Name: Sanazole
CAS#: 104958-90-9
Chemical Formula: C7H11N5O4
Exact Mass: 229.0811
Molecular Weight: 229.2
Elemental Analysis: C, 36.68; H, 4.84; N, 30.56; O, 27.92

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Sanazole; AK 2123; AK-2123; AK2123

IUPAC/Chemical Name: 1H-1,2,4-Triazole-1-acetamide, N-(2-methoxyethyl)-3-nitro-


InChi Code: InChI=1S/C7H11N5O4/c1-16-3-2-8-6(13)4-11-5-9-7(10-11)12(14)15/h5H,2-4H2,1H3,(H,8,13)

SMILES Code: O=C(NCCOC)CN1N=C([N+]([O-])=O)N=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 229.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Sreeja S, Krishnan Nair CK. Tumor control by hypoxia-specific chemotargeting of iron-oxide nanoparticle - Berberine complexes in a mouse model. Life Sci. 2018 Feb 15;195:71-80. doi: 10.1016/j.lfs.2017.12.036. Epub 2017 Dec 28. PubMed PMID: 29289560.

2: Zeng YC, Wu R, Xiao YP, Xin Y, Chi F, Xing R, Xue M, Wang NQ. Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro. Contemp Oncol (Pozn). 2015;19(3):236-40. doi: 10.5114/wo.2015.51820. Epub 2015 Jun 2. PubMed PMID: 26557765; PubMed Central PMCID: PMC4631282.

3: Sreeja S, Nair CK. Anticancer Property of Iron Oxide Nanoparticle-Drug Complexes: An In Vitro Study. J Environ Pathol Toxicol Oncol. 2015;34(3):183-9. PubMed PMID: 26349601.

4: Nair GG, Nair CK. Sanazole directed targeting of silver nanoparticle drug complex to tumor mass: a preclinical investigation in murine model. J Cancer Res Ther. 2014 Oct-Dec;10(4):979-84. doi: 10.4103/0973-1482.148705. PubMed PMID: 25579540.

5: Cherdyntseva NV, Ivanova AA, Ivanov VV, Cherdyntsev E, Nair CK, Kagiya TV. Ascorbic acid glucoside reduces neurotoxicity and glutathione depletion in mouse brain induced by nitrotriazole radiosensitazer. J Cancer Res Ther. 2013 Jul-Sep;9(3):364-9. doi: 10.4103/0973-1482.119303. PubMed PMID: 24125967.

6: Zeng YC, Yu L, Xiao YP, Xin Y, Wang NQ, Zhang XY, Zhao L. Radiation enhancing effects with the combination of sanazole and irinotecan in hypoxic HeLa human cervical cancer cell line. J BUON. 2013 Jul-Sep;18(3):713-6. PubMed PMID: 24065488.

7: Getoff N. Vitamin C: electron emission, free radicals and biological versatility. In Vivo. 2013 Sep-Oct;27(5):565-70. Review. PubMed PMID: 23988889.

8: Yamazaki H, Nakamura S, Nishimura T, Kodani N, Tsubokura T, Kimoto T, Sihomi H, Aibe N, Yoshida K, Koizumi M, Kagiya T. Hypofractionated stereotactic radiotherapy with the hypoxic sensitizer AK-2123 (sanazole) for reirradiation of brain metastases: a preliminary feasibility report. Anticancer Res. 2013 Apr;33(4):1773-6. PubMed PMID: 23564833.

9: Yamazaki H, Nakamura S, Nishimura T, Okabe H, Aibe N, Yoshida K, Kagiya T. Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique. Anticancer Res. 2013 Apr;33(4):1685-8. PubMed PMID: 23564816.

10: Yamazaki H, Nakamura S, Kobayashi K, Tsubokura T, Kodani N, Aibe N, Yoshida K, Kagiya T, Koizumi M, Yamada K. Feasibility trial for daily oral administration of the hypoxic sensitizer AK-2123 (Sanazole) in radiotherapy. Anticancer Res. 2013 Feb;33(2):643-6. PubMed PMID: 23393361.

11: Mathur A, Mallia MB, Banerjee S, Sarma HD, Pillai MR. Preparation and evaluation of a ⁹⁹mTcN-PNP complex of sanazole analogue for detecting tumor hypoxia. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1394-7. doi: 10.1016/j.bmcl.2012.12.079. Epub 2013 Jan 4. PubMed PMID: 23375795.

12: Hassan MA, Furusawa Y, Zhao QL, Takasaki I, Feril LB Jr, Tachibana K, Kudo N, Minemura M, Sugiyama T, Kondo T. Differential cytotoxicity and sonosensitization by sanazole: effect of cell type and acoustic parameters. J Med Ultrason (2001). 2011 Apr;38(2):65-72. doi: 10.1007/s10396-010-0295-2. Epub 2011 Jan 5. PubMed PMID: 27278421.

13: Sakabe T, Murata H, Konishi E, Koto K, Horie N, Matsui T, Sawai Y, Yamazaki H, Kagiya TV, Kubo T. High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report. Sarcoma. 2011;2011. pii: 185465. doi: 10.1155/2011/185465. Epub 2010 Sep 6. PubMed PMID: 20871855; PubMed Central PMCID: PMC2943094.

14: Yu DY, Zhao QL, Wei ZL, Shehata M, Kondo T. Enhancement of hyperthermia-induced apoptosis by sanazole in human lymphoma U937 cells. Int J Hyperthermia. 2009 Aug;25(5):364-73. doi: 10.1080/02656730902967418. PubMed PMID: 19551546.

15: Yu DY, Zhao QL, Wei ZL, Nomura T, Kashiwakura I, Kagiya TV, Kondo T. Enhancement of radiation-induced apoptosis of human lymphoma U937 cells by sanazole. Apoptosis. 2009 May;14(5):655-64. doi: 10.1007/s10495-009-0329-7. PubMed PMID: 19259823.

16: Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash NI, Okkan S, Kagiya TV, Tatsuzaki H. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cancer cervix: initial results of an IAEA multicentre randomized trial. J Cancer Res Ther. 2005 Apr-Jun;1(2):75-8. PubMed PMID: 17998631.

17: Ullal SD, Shenoy KK, Pai MR, Chowta MN, Adiga SM, Dinesh M, Kamath A, Kotian MS, Pai DK. Safety and radiosensitizing efficacy of sanazole (AK 2123) in oropharyngeal cancers: randomized controlled double blind clinical trial. Indian J Cancer. 2006 Oct-Dec;43(4):151-5. PubMed PMID: 17192685.

18: Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash NI, Okkan S, Kagiya VT, Tatsuzaki H. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol. 2007 Jan;82(1):24-9. Epub 2006 Dec 11. PubMed PMID: 17161478.

19: Sugie C, Shibamoto Y, Ito M, Ogino H, Suzuki H, Uto Y, Nagasawa H, Hori H. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res. 2005 Dec;46(4):453-9. PubMed PMID: 16394636.

20: Alam A, Rapthap CC, Singha LI, Sharan RN, Singh V. Radiomodulatory effect of liposome encapsulated AK-2123 on tumor in mice exposed to hepatocarcinogen. Mol Cell Biochem. 2005 Mar;271(1-2):139-50. PubMed PMID: 15881665.